Research programme: anti-cancer therapeutics - TippingPoint Biosciences
Latest Information Update: 11 Oct 2024
At a glance
- Originator TippingPoint Biosciences
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Diffuse intrinsic pontine glioma
Most Recent Events
- 10 Sep 2024 Early research in Diffuse intrinsic pontine gliomain USA (unspecified route) prior to September 2024